Brother Enterprises (002562)2023-04-28 16:00Financial Performance - The company's revenue for Q1 2023 was ¥675,752,812.85, a decrease of 23.14% compared to ¥879,221,669.43 in the same period last year[6] - Net profit attributable to shareholders was ¥10,718,516.56, down 89.60% from ¥103,018,237.25 year-over-year[6] - Basic and diluted earnings per share were both ¥0.01, reflecting a decrease of 90.00% from ¥0.10 in the same period last year[6] - Total operating revenue for Q1 2023 was ¥675,752,812.85, a decrease of 23.1% compared to ¥879,221,669.43 in the same period last year[22] - Net profit for Q1 2023 was ¥10,718,516.56, a significant decline of 89.6% from ¥103,018,237.25 in Q1 2022[24] - The total comprehensive income for the first quarter was -29,572,064.37 CNY, compared to 167,620,895.50 CNY in the previous year[25] Cash Flow and Assets - The net cash flow from operating activities was -¥76,031,415.32, a decline of 133.97% compared to -¥32,496,893.14 in the previous year[6] - Cash inflow from operating activities totaled 650,812,843.23 CNY, slightly up from 649,826,097.25 CNY year-over-year[26] - The company's cash and cash equivalents decreased to ¥1,943,907,962.62 from ¥2,066,298,704.11 year-over-year[20] - The ending balance of cash and cash equivalents was 383,906,155.97 CNY, down from 555,882,323.20 CNY at the end of the previous year[27] - Cash flow from investing activities generated a net inflow of 129,306,842.89 CNY, compared to 54,600,695.43 CNY in the same period last year[27] - Cash flow from financing activities resulted in a net inflow of 21,289,785.10 CNY, improving from -18,738,343.65 CNY year-over-year[27] Investments and Expenses - The company reported a significant increase in investment income, reaching ¥38,285,246.98, up 391.17% from ¥7,794,658.72 in the previous year[9] - Research and development expenses decreased by 52.37% to ¥16,052,887.38 from ¥33,703,410.70 in the same period last year[9] - The company plans to invest a total of RMB 2.5 billion in the construction of an international pharmaceutical industry base, with RMB 1.5 billion allocated for fixed asset investment and RMB 1 billion for R&D and other investments[14] Shareholder Information - The total number of common shareholders at the end of the reporting period was 56,110[12] - The company has a significant shareholder, Qian Zhida, holding 24.22% of shares, and another major shareholder, Qian Zhiming, holding 20.15%[12] - The company has pledged shares amounting to 90 million by Qian Zhida and 30 million by Qian Zhiming[12] - The company has a total of 10 major shareholders, with the top two holding over 44% of the shares combined[12] Liabilities and Tax - The company reported a significant increase in tax payable, which rose by 67.77% to ¥27,297,243.53 from ¥16,270,535.78 in the previous year[9] - Total liabilities for Q1 2023 were ¥2,266,970,405.68, down from ¥2,326,094,438.77 in the previous year[20] Other Information - The company received government subsidies amounting to ¥1,391,180.07, which are closely related to its normal business operations[7] - The company experienced a 49.79% decrease in contract liabilities, which fell to ¥11,341,546.20 from ¥22,589,429.66 due to the delivery of previously received advance payments[9] - The company is in the process of acquiring land for the pharmaceutical project, which is subject to legal bidding procedures, introducing some uncertainty regarding the timeline[14] - The first quarter report was not audited[28]